investingisatrickygame
03 Jul 2017
AGM Presentation 30th June 2017 Just posted[link]
Spadeychops
03 Jul 2017
Eden - nice article [link]
ReynardThree
30 Jun 2017
Re: Yet Another RNS (AGM) I like the paragraph:'Over the last year, Eden has started selling product on a commercial scale, which has moved us from being solely in a development phase to the commercialisation stage. We are now well positioned to build on this and all the development work that we have invested in to date.' With a market cap of only £23million, surely we are now set for some significant share price improvement?
ash6666
30 Jun 2017
Yet Another RNS (AGM) Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, will hold its AGM today at 12.00pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED. At the meeting Eden's Chairman, Tom Lupton, will make the following statement: Since our last AGM, the Company has seen the first commercial sales of 3AEY in Italy, Spain and Greece; received registration of 3AEY in France, as well as other countries within the southern EU zone; signed an exclusive distribution agreement with Eastman Chemical for our nematicide product; and expanded its team through the appointment of experienced sector experts. We have also today announced the signing of a number of important commercial agreements with Sipcam SpA who, at the same time, have made a strategic investment in Eden. This, in itself, is an important event which serves as a platform upon which we will be able to maximise the value of Eden, its products and technologies. All of this, I hope, goes to show the significant progress that has been made over the last twelve months. And yet, the next twelve months is set to be even better for Eden with first commercial sales of 3AEY in France in 2017; product registrations progressing in several regions, including the USA; distribution agreements to be signed covering multiple territories for 3AEY and other products; the launch of Bayer Animal Health's pet products; the launch of TerpeneTech's head-lice product; and research and development work being undertaken which will help to strengthen the Company's portfolio of products. The Company is well-positioned to grow; by building market acceptance, share and reach of its products through strong partners, such as Sipcam, Eastman Chemical and Bayer Animal Health; by funding product and technology development through the resources that it now has available to it; by developing its own branding, including Sustaineä which will become increasingly well-known and sought after in the sectors in which Eden's technologies and products are commercialised. The market for natural and naturally-derived products and technologies such as ours continues to grow at a rapid rate and we are pleased to be in a position to take full advantage of this. Over the last year, Eden has started selling product on a commercial scale, which has moved us from being solely in a development phase to the commercialisation stage. We are now well positioned to build on this and all the development work that we have invested in to date. There is still much to do and more value to be derived and our expanded team will be concentrating its efforts on delivering this over the next twelve months.
ash6666
30 Jun 2017
Re: Another RNS Subscription now completed (RNS)
ash6666
30 Jun 2017
Another RNS Eden Research Plc("Eden" or "Company"
Sipcam commercial agreements, proposed Sipcam investment and proposed institutional placing Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough biocontrol products and natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that it has signed multiple new commercial and development agreements with its partner, Sipcam SpA ("Sipcam", representing a significant expansion of the Company's existing relationship with them. In addition to expanding the commercialisation "footprint" for 3AEY to include Australia, the companies are formalising their relationship as collaborators, and Eden is granting Sipcam the right to exclusively distribute Eden products in a range of new countries, including some of the largest markets for agrochemicals in the world. As part of Sipcam's overall commitment to the relationship with Eden (in addition to the Subscription (defined below)), in connection with the signed agreements, financial terms have been agreed which include an upfront cash payment to Eden of €0.6m and potential further future fees which are dependent upon which rights, if any, Sipcam decides to take. The Company also announces that it proposing to raise in aggregate c.£2.4m (before expenses) through a subscription of up to 20,494,330 new ordinary shares of 1 pence each in the Company ("Ordinary Shares" (the "Subscription Shares" and an institutional placing of up to 1,915,888 new Ordinary Shares (the "Placing Shares" (the "Placing" both at a price of 10.7 pence per new Ordinary Share. Sipcam is proposing to make a strategic investment of c.£2.2m in the Company and to enter into a subscription agreement to subscribe for the Subscription Shares (the "Subscription". Commercial and Development Agreements with Sipcam The agreements with Sipcam are summarised as follows: · Collaboration and Evaluation & Option Agreements- Provides Sipcam with the first right to negotiate for the distribution rights for new plant protection products that Eden develops in countries where Sipcam has an affiliate, subject to certain ongoing commitments and evaluations.- Grants Eden access to Sipcam-owned technologies and R & D facilities.- Grants Sipcam the right to evaluate a number of Sipcam-Oxon Group's active substances encapsulated using Eden's Sustaineä microencapsulation technology. This includes combinations with Eden's own active ingredients.- Provides a framework agreement for subsequent licence and/or supply agreements under the collaboration. · Distribution Agreements- Eden has agreed to appoint Sipcam as Eden's exclusive distributor in Italy, Spain and Australia for 3AEY.- 3AEY is Eden's first product that targets botrytis on grapes and a range of additional high value fruits and vegetables. It is sold as 3logyâ in Italy and Arawâ in Spain.- The existing licence agreements with Sipcam (covering Italy and Spain) will be terminated and replaced with the new distribution agreements reflecting the evolution of Eden's business model (from licensing to product sales) and providing Eden with the potential for both additional [future] revenue and improved profits. Proposed Subscription and Placing The Company is proposing to raise c.£2.4m (before expenses) through the Subscription and the Placing. The net proceeds of the Subscription and Placing would be used to: · Register existing and new products and increase the global reach of existing Eden products· Commence new R&D trials in both plant protection products and personal care applications· Pursue commercialisation of animal health products outside of the United States· Expand business and brand development activitiesSipcam is proposing to enter into a su
ash6666
29 Jun 2017
RNS New terms agreed with UMMS for licence to next-generation technology Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough biocontrol products and natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that it has agreed new terms covering its licence agreement with University of Massachusetts Medical School ("UMMS". In Eden's 2016 Report and Accounts it was noted that an amount of £570,462, (USD$700,000) had been accrued to UMMS for minimum royalties payable under the licence agreement which Eden signed with UMMS in 2011. Eden has now agreed with UMMS to revise the minimum royalties from October 2017, resulting in a net reduction in Eden's short-term financial obligations to UMMS, with the amount accrued being written off in its entirety. Eden has achieved this by signing an Amendment with UMMS, for which Eden has agreed to pay a fee of USD$250,000. A portion of this fee is payable upon signature of the Amendment, and the balance is payable in one year's time. Sean Smith, Chief Executive of Eden, said: "We are pleased to announce the re-setting of some of the key commercial terms of our licence agreement with UMMS. We believe that the new terms reflect both the long term potential of our next-generation encapsulation technology whilst also reflecting the current stage of technology development. We look forward to the ongoing collaboration with UMMS which is, in part, focussed on the further development of this technology with the objective of creating a next-generation encapsulation system to help us solve a broader set of challenges for our partners."
ash6666
11 Jun 2017
From LSE From cuppat.-----[link] the natural defenses of the plantFungicide manufacturers are aware of the challenges and review hundreds of thousands of new active ingredients. However, finding effective materials that are also safe for the environment, workers and consumers is extremely complicated.As Rucker of Bayer Crop Science commented, "Currently, our company requires more than ten years of development and $200 million of investment to introduce a new active ingredient to the market, from its discovery to the final development."A promising research area that can help meet the challenges of fungicide resistance is to create a product that reinforces the natural defenses of plants."Traditionally, companies that manufacture plant protection products have concentrated on developing fungicides that can protect the plant directly to avoid being infected by a pathogen, or fungicides that fight pathogens, after infection." In recent years, several products have been discovered that instead of promoting healthier plants, they seem to better fight pests for themselves, "says Rucker.Rucker mentions that Bayer Crop science is developing several "biological" products. "While some of these products work effectively against pests, in most cases, biological products offer a certain type of natural ' shield ' that protects plants and helps them be healthier to fend off pest attacks." "This is a very interesting new area for research, because we don't know exactly how these products work and we are discovering more and more about them with each year."
investingisatrickygame
08 Jun 2017
Top Grape Growing Countries [link] modified 16th March 2017Then this, also March 2017[link] in theory, if Sipcam and Sumi-Agro in France, Spain and Italy can be successful with Mevalone and in due course secure maybe 20% market share (as has happened in some regions last year and RNS'd) then of those combined 134 million hectolitres of wine produced, Mevalone could service 27 million hectolitres per annum, not allowing for any increase in crop yield by offsetting the effect of botrytis.A hectolitre is equal to 100 litres [link] want to do the maths on what that relates to in potential Mevalone sales for these three countries?
ash6666
05 Jun 2017
Re: Annual Report and AGM .........As mentioned above, the 2016 results benefitted from the first sales of 3AEY in Italy, Greece and Spain. In total, 2016 sales of 3AEY (at the distributor level) were in excess of €1m with over 85,000 litres sold throughout the year. This was comfortably above what our partners and we had forecast in these territories, which is encouraging, particularly in light of the fact that botrytis was not especially prevalent this last season and authorisation in Italy was granted somewhat later than required for full promotion via certain product catalogues. Nevertheless, in some regions our products achieved a market share of approximately 20%, which is a remarkable achievement for a new product to market.
ash6666
05 Jun 2017
Annual Report and AGM Posting of Annual Report & Notice of AGM Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural bio-control products and microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that its Annual Report and Accounts for the year ended 31 December 2016, Notice of the Annual General Meeting ("AGM" and a Form of Proxy have been posted to shareholders and are now available on the Company's website: www.edenresearch.com The AGM is to be held on Friday 30 June 2017 at 12.00pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED.
ReynardThree
31 May 2017
Re: Anyone Speak French? Seems to be a fair bit of competition out there, according to this article. According to Google translate, the section referring to Eden reads:Another highly anticipated innovation, which we discussed in our columns last year, Eden Research's anti-botrytis "3AEY" will be marketed by Sumi Agro as Mevalone. This product is based on encapsulated terpene technology. "It acts as early curative, informs Antoine Meyer, president of Sumi Agro France. The reasoning of the positioning is therefore very important. Well placed, efficiencies of 70 to 80% are obtained, as much as with conventional products. Usable from stage B up to three days before harvest, the product does not have an MRL. Mevalone is limited to 4 applications per year at a rate of 4 l / ha, and increases in efficiency coupled with Action Pin adjuvant, also based on terpenes.
ash6666
31 May 2017
Anyone Speak French? [link]
investingisatrickygame
24 May 2017
Global Market Size For Eden's 3AEY [link] article is from 2015, but under the header of "The Pesticide Problem" it tells us that the volume market for pesticides for the French grape industry was 60,000 tonnes per annum. I am assuming therefore, that this is 60 million litres per annum. I am happy to be clarified on this.France is Europe's greatest user of pesticides by volume.Sumi-Agro France has specifically contracted with Eden to resolve this problem.Last year, Sipcam in their first use of 3AEY has 20% penetration in some geographies, as RNS'd by Eden. So, in time, if Sumi-Agro could reach up to 20% market share in France, this would imply product sales of 12 million litres.Back to last year's AGM example of changed pricing model., Slide 11 [link] based on 1 million litres sold. In this example, Eden would receive net income of 12 x 1 x 2.5 million euros, namely 30 million euros, namely £26 million PER ANNUMEven if the litres conversion is slightly out, they don't get to 20% market share and the exchange rate fluctuates a bit, it is clear to see that potential future income generated from France alone is substantial. Add in Italy and Spain and 3AEY is a very healthy revenue and profit line in Eden's accounts.
ash6666
24 May 2017
News [link]
